


Stabilis



N-acetylcysteine



Noms commerciaux

Acetadote	Etats Unis d'Amérique, Nouvelle Zélande
Acetylcystein	Australie, Canada, Danemark
Acetylcysteine	Grande Bretagne, Iran
Cilol	Inde
Fluimucil	Allemagne, Colombie, Equateur, Hongrie, Pays bas, Pérou, Pologne, Portugal, Suisse
Hidonac	Espagne, France, Italie, Malaisie, Roumanie
Mucare	Inde
Mucofrin	Italie
Mucomelt	Inde
Mucomix	Inde
Mucosys	Inde
Nacel	Inde
Parvolex	Canada, Grande Bretagne, Grèce, Irlande



Stabilité des solutions

PVC		60 mg/ml	23-27°C		72			4639
PVC		26 mg/ml	25°C		60			2076
PVC		60 mg/ml	23-27°C		72			4639
PVC		60 mg/ml	23-27°C		72			4639
POF		25 mg/ml	2-8°C		4			4727
POF		25 mg/ml	23-27°C		24			4727



Stabilité en mélange

								
		25 mg/ml	2-8°C		Zinc gluconate : 62.5 µg/mL	8		4727
		25 mg/ml	23-27°C		Zinc gluconate : 62.5 µg/mL	4		4727



Compatibilités

				
		N-acetylcysteine : 200 mg/ml Aciclovir sodium : 50 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Amikacin sulfate : 250 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Aminophylline : 50 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Amiodarone hydrochloride : 50 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		N-acetylcysteine : 200 mg/ml Amphotericin B	Ø	3766
		N-acetylcysteine : 200 mg/ml Ampicillin sodium	Ø	3766
		N-acetylcysteine : 200 mg/ml Atropine sulfate : 0.4 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Azithromycine : 500 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Bretylium tosilate : 50 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Caffeine : 10 mg/ml	Ø	3964
		N-acetylcysteine : 200 mg/ml Caffeine : 10 mg/ml	Ø	3766
		N-acetylcysteine		4639
		N-acetylcysteine		4639
		N-acetylcysteine : 200 mg/ml Calcium chloride : 78 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Calcium gluconate : 100 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Caspofungin acetate	Ø	3766
		N-acetylcysteine : 200 mg/ml Cefazolin sodium	Ø	3766
		N-acetylcysteine : 100 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141

		N-acetylcysteine : 200 mg/ml Cefotaxime sodium	Ø	3766
		N-acetylcysteine : 200 mg/ml Cefoxitin sodium	Ø	3766
		N-acetylcysteine : 100 mg/ml Ceftazidime : 83.3 mg/ml		1759
		N-acetylcysteine : 100 mg/ml Ceftazidime : 125 mg/ml		2141
		N-acetylcysteine : 200 mg/ml Ceftazidime	Ø	3766
		N-acetylcysteine : 200 mg/ml Ceftriaxone disodium	Ø	3766
		N-acetylcysteine : 200 mg/ml Chlorpromazine hydrochloride : 25 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Ciclosporin : 50 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Ciprofloxacin lactate : 2 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Clindamycin phosphate : 150 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Co-trimoxazole : 16/80 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Dexamethasone sodium phosphate : 4 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml	RL	4603
		N-acetylcysteine		4639
		N-acetylcysteine : 200 mg/ml Cefuroxime sodium	Ø	3766
		N-acetylcysteine : 200 mg/ml Cloxacillin sodium	Ø	3766
		N-acetylcysteine : 200 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		N-acetylcysteine : 200 mg/ml Dexmedetomidine : 100 µg/ml		4389
		N-acetylcysteine : 200 mg/ml Diazepam : 5 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Digoxin : 50 µg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Diphenhydramine hydrochloride : 50 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Dobutamine hydrochloride : 12.5 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Dopamine hydrochloride : 3.2 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Droperidol : 2.5 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Enalaprilate : 1.25 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Epinephrine hydrochloride : 1000 µg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Erythromycin lactobionate	Ø	3766

		N-acetylcysteine : 200 mg/ml Fentanyl citrate : 50 µg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Fluconazole : 2 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Furosemide : 10 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Gentamicin sulfate : 40 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Heparin sodium : 1000 UI/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Hydralazine hydrochloride	Ø	3766
		N-acetylcysteine : 200 mg/ml Hydrocortisone sodium succinate	Ø	3766
		N-acetylcysteine : 200 mg/ml Insulin : 100 UI/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Labetalol hydrochloride : 5 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Lidocaine hydrochloride : 1 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Mannitol : 250 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Meropenem : 50 mg/ml		4319
		N-acetylcysteine : 200 mg/ml Metronidazole : 5 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Midazolam hydrochloride : 5 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Milrinone lactate : 1 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Naloxone hydrochloride : 0.4 mg/ml	Ø	3408
		N-acetylcysteine : 200 mg/ml Nitroglycerin : 5 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Norepinephrine bitartrate : 1 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Piperacillin sodium	Ø	3766
		N-acetylcysteine : 200 mg/ml Piperacillin sodium / tazobactam	Ø	3766
		N-acetylcysteine : 200 mg/ml Potassium chloride : 200 mEq/l	Ø	3766
		N-acetylcysteine : 200 mg/ml Propranolol hydrochloride : 1 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Ranitidine hydrochloride : 25 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Rocuronium bromide : 10 mg/ml	Ø	3766
		N-acetylcysteine : 200 mg/ml Sodium bicarbonate : 84 mg/ml	Ø	3766
		N-acetylcysteine : 100 mg/ml Sugammadex : 100 mg/ml	Ø	3372

	N-acetylcysteine : 100 mg/ml Temocilline : 83.33 mg/ml		2231
	N-acetylcysteine : 200 mg/ml Ticarcillin / clavulanic acid : 31 mg/ml		3766
	N-acetylcysteine : 100 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
	N-acetylcysteine : 200 mg/ml Verapamil hydrochloride : 2.5 mg/ml		3766



Voie d'administration



Bibliographie


	Type	Source
1759	Revue	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
2076	Revue	Dribben WH, Porto SM, Jeffords BK. Stability and microbiology of inhalant N-acetylcysteine used as an intravenous solution for the treatment of acetaminophen poisoning. Ann Emerg Med 2003 ; 42: 9-13.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.

3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4639	Revue	Friciu M, Monfort A, Dubé P-A, Leclair G. Stability of N-Acetylcysteine 60 mg/mL in Extemporaneously Compounded Injectable Solutions. Can J Hosp Pharm 2021 2021;74(4):344-9
4727	Revue	Primas N, Lano G, Brun D, Curti C, Sallée M, Sampol-Manos E, Lamy E, Bornet C, Burtsey S, Vanelle P. Stability Study of Parenteral N-Acetylcysteine, and Chemical Inhibition of Its Dimerization Pharmaceuticals 2023 ;16,72

Stabilis



N-acetylcysteine



Stabilité des préparations

		7,5 ml Parvolex 20 %®	Chlorure de benzalkonium Isopto Tears® 7 ml	0.16% - 0.5 ml 2-8°C	?	90		2558
		1500mg=7.5ml Mucosil®	Chlorobutanol 37.5ml Liquidfilm Tears® 7.5ml	2-8°C	?	35		2426
		1500mg=7.5ml Mucosil®	Chlorobutanol 37.5ml Liquidfilm Tears® 7.5ml	23-25°C	?	30		2426
		7,5 ml Parvolex 20 %®	Chlorure de benzalkonium Isopto Tears® 7 ml	0.16% - 0.5 ml 25°C	?	41		2558



Facteur influençant la stabilité

				2426
--	--	--	--	------




Bibliographie

	Type	Source
2426	Revue	Anaizi NH, Swenson CF, Dentinger PJ. Stability of acetylcysteine in an extemporaneously compounded ophthalmic solution Am J Health-Syst Pharm 1997 ; 54: 549-553.
2558	Revue	Fawcett JP, Woods DJ, Hayes P. The stability of acetylcysteine eyedrops. Aust J Hosp Pharm 1993 ; 23: 18-21.

Stabilis



N-acetylcysteine



Stabilité des préparations


90 ml acetylcysteine sodium 10%		Edulcorant 7 ml Arôme fraise 7 ml	23-25°C		35			2395
100 mg @=2 Acetylcysteine Hospira		NaCl 0.9% + bactériostatique >> 20 ml	25°C		60			3165
2000 mg @=2 Acetylcysteine Hospira		NaCl 0.9% + bactériostatique >> 20 ml	25°C		60			3165
90 ml acetylcysteine sodium 10%		Edulcorant 7 ml Arôme fraise 7 ml	3-5°C		35			2395
600 mg / 3 mL Acetylcystene 20% Hospira			2-8°C		180			2400




Bibliographie

	Type	Source
2395	Revue	Siden R, Johnson CE. Stability of a flavored formulation of acetylcysteine for oral administration Am J Health-Syst Pharm 2008 ; 65: 558-561.
2400	Revue	Kiser TH, Oldland AR, Fish DN. Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings Am J Health-Syst Pharm 2007 ; 64: 762-766.
3165	Revue	Fohl AL, Johnson CE, Cober P. Stability of extemporaneously prepared acetylcysteine 1% and 10% solutions for treatment of meconium ileus Am J Health-Syst Pharm 2011 ; 68: 69-72.

Stabilis



N-acetylcysteine



Stabilité en mélange

	25°C		Formoterol fumarate : Spécialité pharmaceutique 20 µg/2mL 1 3498
	Aucun	21-25°C	Levalbuterol : Liquide @=? Levalbuterol Sepracor® 0.22 mg/0.5 2803
	Aucun	23-27°C	Netilmicin sulfate : Flacon injectable Netromicine® 1000 mg 1 2648 Betamethasone sodium phosphate : Flacon injectable Celestene® 8 mg = 2
	25°C		Arformoterol : Spécialité pharmaceutique Brovana® 15 µg/2 mL 0.5 3019
	Aucun	25°C	Ipratropium bromide : Liquide Atrovent® 104 µg/ml 1 2787
	Aucun	25°C	Fenoterol : Liquide Berotec® 243 µg/ml 7 2787



Compatibilités

	N-acetylcysteine Salbutamol sulfate 549



Bibliographie

Type	Source
549 Revue	Owsley HD, Rusho WJ. Compatibility of common respiratory therapy drug combinations. Int J Pharm Compound 1997 ; 1: 121-122.

2648	Revue	Rieutord A, Arnaud P, Dauphin JF, Brion F. Stability and compatibility of an aerosol mixture including N-acetylcysteine, netilmicin and betamethasone Int J Pharm 1999 ; 190, 1: 103-107.
2787	Revue	Lee TY, Chen CM, Lee CN, Chaing YC. Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium. Am J Health-Syst Pharm 2005 ; 62, 8: 828-833.
2803	Revue	Bonasia PJ, McVicar WK, Williams B, Ong S. Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium or acetylcysteine sodium. Respiratory Care 2008 ; 683, 12: 1716-1722.
3019	Revue	Bonasia P, Cook C, Cheng Y et al. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. Curr Med Res Opin 2007 ; 23: 2477-2483.
3498	Revue	Akapo S, Gupta J, martinez E, Mccrea C, Ye L, Roach M Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. Ann Pharmacotherapy 2008 ; 42, 10: 1416-1424.



Dictionnaire

	Antidote		injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	Chlorure de sodium 0,9%		Lumière
	Heure		Glucose 5%
	Non précisée		Chlorure de sodium 0,45%
	Polyolefine		A l'abri de la lumière
	Jour		Stabilité en mélange
	Solvant		Molécule
	Compatibilités		Incompatibilité non précisée
	Incompatible		Aucun
	Compatible		Instabilité chimique
	Eau pour préparation injectable		Ringer lactate
	Voie d'administration		Perfusion intraveineuse
	Perfusion continue		Bibliographie
	Divers		Collyre
	Stabilité des préparations		Origine
	Excipient		Polyéthylène
	Flacon injectable		Facteur influençant la stabilité
	Augmentation		Provoque
	Dégradation		Solution buvable
	Flacon plastique		Liquide
	Seringue PP orale		Aérosol
	Verre		Non précisé
	Dictionnaire		